A 13-years pharmacovigilance analysis of novel hormonal agents in prostate cancer using the FDA adverse event reporting system database
Our study offers a comprehensive overview of safety signals associated with NHAs, providing a valuable reference for drug selection and future prospective research.
Authors
- Tao Qin (ORCID: https://orcid.org/0000-0003-0533-0036)
- Ning Chen (ORCID: https://orcid.org/0000-0002-8191-6744)
- Liang Ai
- Lisha Wu (ORCID: https://orcid.org/0000-0002-0870-5342)
- Haiwei Xiao
- Yanping Wen (ORCID: https://orcid.org/0009-0002-9877-6482)
- Linhui Cao (ORCID: https://orcid.org/0000-0002-0463-2721)
Institutions
- Guangzhou University of Chinese Medicine (CN)
- Sun Yat-sen University (CN)
- Sun Yat-sen Memorial Hospital (CN)
Publication Details
- Journal
- Expert Opinion on Drug Safety
- Published
- 2024-12-13
- DOI
- https://doi.org/10.1080/14740338.2024.2442514
- Citations
- 2
- Primary Topic
- Pharmacovigilance and Adverse Drug Reactions
- Type
- article
- Field-Weighted Citation Impact
- 0.70
Funders
- Beijing Xisike Clinical Oncology Research Foundation